# Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

> **NCT02696434** · PHASE3 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 101 (actual)

## Conditions studied

- Opioid Use Disorder

## Interventions

- **DRUG:** Naltrexone
- **DRUG:** Placebo
- **DRUG:** Buprenorphine

## Key facts

- **NCT ID:** NCT02696434
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-11
- **Final completion:** 2017-11-30
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2019-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02696434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02696434, "Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02696434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*